Answers are grounded in this paper and cite their sources.
Sarilumab is an alternative to biologic DMARDs or targeted synthetic DMARDs in patients with moderate to severely active RA who have not responded adequately to prior conventional synthetic DMARDs or tumor necrosis factor-α inhibitors.
No takes yet. Share an insight, caveat, or question.
Boyce et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: